CORRECTING and Replacing – GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to Patients

August 13, 2021

Potential to provide approximately $15 million a year in savings for life-enhancing medications
SANTA MONICA, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) — In a release issued earlier today by GoodRx, Inc. (Nasdaq: GDRX), please note the announcement has been revised to include information about Synjardy, Synjardy XR and Stiolto Respimat.

Read the source article at Aktien
2021-08-09 15:16:00

Share This Story!